MAYPHARM Unveils HYALMASS AQUATOX, a Next-Generation Multi-Active Skin Solution for the Global Aesthetic Market

  • September 26, 2026
  • Posted by: Victoria Reynolds
  • Category: Funding trends
No Comments
MAYPHARM Unveils HYALMASS AQUATOX, a Next-Generation Multi-Active Skin Solution for the Global Aesthetic Market
MaypharmSeptember 26, 2026

SEOUL, South Korea, Sept. 26, 2026 /PRNewswire/ — MAYPHARM, a global aesthetic and cosmeceutical company, has announced the upcoming launch of HYALMASS AQUATOX, introducing a new multi-active formulation designed to respond to the rapidly evolving demands of the global aesthetic market.

Rather than relying on a single trending ingredient, HYALMASS AQUATOX brings together five high-interest active ingredients — PDRN, Exosomes, Botulinum Peptide, GHK-Cu, and Succinic Acid — in one advanced aesthetic formulation.

Five Powerful Actives. One Advanced Formula.

Botulinum Peptide — designed to support a smoother, more refined skin appearance

GHK-Cu — a copper peptide widely studied for skin conditioning and regeneration-related applications

Succinic Acid — recognized for its role in skin revitalization and antioxidant-related activity

PDRN — associated with skin regeneration and recovery

Exosomes — increasingly recognized for their role in advanced skin rejuvenation approaches

By combining these highly sought-after ingredients, HYALMASS AQUATOX aims to address the growing global demand for multifunctional, ingredient-driven aesthetic solutions.

A New Chapter for the HYALMASS Portfolio

The launch follows the growing international interest in HYALMASS AQUA EXOSOME, strengthening MAYPHARM’s expanding presence in the global aesthetic market.

As demand for advanced skin rejuvenation products continues to develop, the market has also seen an increasing number of products adopting similar ingredient concepts, visual identities, and positioning. MAYPHARM therefore emphasizes the importance of product authenticity and authorized distribution when purchasing HYALMASS products.

Distributors, aesthetic professionals, and customers are encouraged to verify the original manufacturer, authorized supply channel, packaging, and official product information before purchasing or using HYALMASS products.

Innovation That Moves With the Market

With HYALMASS AQUATOX, MAYPHARM continues to expand its portfolio around emerging aesthetic trends while combining multiple high-interest actives into a single product concept.

Five actives. One formula. A new direction for advanced skin care.

HYALMASS AQUATOX — Coming Soon.

Choose the Original. Choose MAYPHARM.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/maypharm-unveils-hyalmass-aquatox-a-next-generation-multi-active-skin-solution-for-the-global-aesthetic-market-302890701.html

SOURCE Maypharm

Distributed by PR Newswire / Cision.



Author: Victoria Reynolds
Victoria Reynolds writes about health and science for legal Statement, covering clinical trial updates, treatment approvals, and research developments spanning both medical and broader scientific topics. She's especially attentive to presenting health and science news accurately, without overstating early-stage findings or clinical results. Victoria's writing style is careful and precise, reflecting the responsibility that comes with health-related reporting, while remaining accessible for readers without a scientific background. She's drawn to stories that track the practical progress of medical research, from early trial phases to regulatory milestones, and she consistently reminds readers that her coverage is informational rather than medical guidance.